249 related articles for article (PubMed ID: 28838417)
21. Trefoil factor-3 is not a useful marker of mucosal healing in Crohn's disease treated with anti-TNF-α antibodies.
Eder P; Stawczyk-Eder K; Korybalska K; Czepulis N; Luczak J; Lykowska-Szuber L; Krela-Kazmierczak I; Linke K; Witowski J
World J Gastroenterol; 2017 Jan; 23(1):135-140. PubMed ID: 28104989
[TBL] [Abstract][Full Text] [Related]
22. Mucosal healing at 3 months predicts long-term endoscopic remission in anti-TNF-treated luminal Crohn's disease.
af Björkesten CG; Nieminen U; Sipponen T; Turunen U; Arkkila P; Färkkilä M
Scand J Gastroenterol; 2013 May; 48(5):543-51. PubMed ID: 23477356
[TBL] [Abstract][Full Text] [Related]
23. Certolizumab pegol: new drug. As a last resort in Crohn's disease: continue to use other TNF alpha inhibitors.
Prescrire Int; 2009 Jun; 18(101):108-10. PubMed ID: 19637418
[TBL] [Abstract][Full Text] [Related]
24. Intravenous Versus Subcutaneous Anti-TNF-Alpha Agents for Crohn's Disease: A Comparison of Effectiveness and Safety.
Liu J; Sylwestrzak G; Ruggieri AP; DeVries A
J Manag Care Spec Pharm; 2015 Jul; 21(7):559-66. PubMed ID: 26108380
[TBL] [Abstract][Full Text] [Related]
25. Crohn's disease - treatment with biological medication.
Zaltman C; Amarante H; Brenner MM; Costa MHM; Flores C; Leal RF; Grain JFS; Zeroncio M
Rev Assoc Med Bras (1992); 2019 May; 65(4):554-567. PubMed ID: 31066809
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and Safety Profile of Anti-tumor Necrosis Factor-α Versus Anti-integrin Agents for the Treatment of Crohn's Disease: A Network Meta-analysis of Indirect Comparisons.
Miligkos M; Papamichael K; Vande Casteele N; Mantzaris GJ; Gils A; Levesque BG; Zintzaras E
Clin Ther; 2016 Jun; 38(6):1342-1358.e6. PubMed ID: 27091732
[TBL] [Abstract][Full Text] [Related]
27. Factors Contributing to the Preference of Korean Patients with Crohn's Disease When Selecting an Anti-Tumor Necrosis Factor Agent (CHOICE Study).
Kim ES; Kim KO; Jang BI; Lee CK; Kim HJ; Lee KM; Kim YS; Eun CS; Jung SA; Yang SK; Lee J; Kim TO; Jung Y; Seo GS; Yoon SM;
Gut Liver; 2016 May; 10(3):391-8. PubMed ID: 26347512
[TBL] [Abstract][Full Text] [Related]
28. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
29. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed.
Sands BE; Feagan BG; Rutgeerts P; Colombel JF; Sandborn WJ; Sy R; D'Haens G; Ben-Horin S; Xu J; Rosario M; Fox I; Parikh A; Milch C; Hanauer S
Gastroenterology; 2014 Sep; 147(3):618-627.e3. PubMed ID: 24859203
[TBL] [Abstract][Full Text] [Related]
30. Vedolizumab for ulcerative colitis and Crohn's disease: results and implications of GEMINI studies.
Lam MC; Bressler B
Immunotherapy; 2014; 6(9):963-71. PubMed ID: 25341118
[TBL] [Abstract][Full Text] [Related]
31. Substitution with Alternative Anti-TNFα Therapy (SAVANT)-Outcomes of a Crohn's Disease Cohort Undergoing Substitution Therapy with Certolizumab.
Boktor M; Motlis A; Aravantagi A; Sheth A; Jordan P; Morris J; Manas K; Hussain N; Cvek U; Trutschl M; Becker F; Alexander JS
Inflamm Bowel Dis; 2016 Jun; 22(6):1353-61. PubMed ID: 27104819
[TBL] [Abstract][Full Text] [Related]
32. The influence of anti-TNF therapy on the magnetic resonance enterographic parameters of Crohn's disease activity.
Eder P; Katulska K; Krela-Kaźmierczak I; Stawczyk-Eder K; Klimczak K; Szymczak A; Linke K; Łykowska-Szuber L
Abdom Imaging; 2015 Oct; 40(7):2210-8. PubMed ID: 26048698
[TBL] [Abstract][Full Text] [Related]
33. Genetic polymorphisms predict response to anti-tumor necrosis factor treatment in Crohn's disease.
Netz U; Carter JV; Eichenberger MR; Dryden GW; Pan J; Rai SN; Galandiuk S
World J Gastroenterol; 2017 Jul; 23(27):4958-4967. PubMed ID: 28785150
[TBL] [Abstract][Full Text] [Related]
34. [Efficacy of tumor necrosis factor-alpha inhibitors in fistulising perianal Crohn's disease].
Bor R; Farkas K; Bálint A; Szűcs M; Abrahám S; Baradnay G; Wittmann T; Szepes Z; Nagy F; Molnár T
Orv Hetil; 2013 Dec; 154(49):1943-8. PubMed ID: 24292112
[TBL] [Abstract][Full Text] [Related]
35. Certolizumab pegol for the management of Crohn's disease in adults.
Rivkin A
Clin Ther; 2009 Jun; 31(6):1158-76. PubMed ID: 19695385
[TBL] [Abstract][Full Text] [Related]
36. Mucosal expression of basic fibroblastic growth factor, syndecan 1 and tumour necrosis factor-α in Crohn's disease in deep remission under treatment with anti-TNFα antibodies.
Tursi A; Elisei W; Principi M; Inchingolo CD; Nenna R; Picchio M; Giorgio F; Ierardi E; Brandimarte G
J Gastrointestin Liver Dis; 2014 Sep; 23(3):261-5. PubMed ID: 25267953
[TBL] [Abstract][Full Text] [Related]
37. Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn's disease with prior loss of response to infliximab.
Feagan BG; Sandborn WJ; Wolf DC; Coteur G; Purcaru O; Brabant Y; Rutgeerts PJ
Aliment Pharmacol Ther; 2011 Mar; 33(5):541-50. PubMed ID: 21223344
[TBL] [Abstract][Full Text] [Related]
38. Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease.
Bohm M; Xu R; Zhang Y; Varma S; Fischer M; Kochhar G; Boland B; Singh S; Hirten R; Ungaro R; Shmidt E; Lasch K; Jairaith V; Hudesman D; Chang S; Lukin D; Swaminath A; Sands BE; Colombel JF; Kane S; Loftus EV; Shen B; Siegel CA; Sandborn WJ; Dulai PS;
Aliment Pharmacol Ther; 2020 Aug; 52(4):669-681. PubMed ID: 32656800
[TBL] [Abstract][Full Text] [Related]
39. Genetic Markers Predict Primary Non-Response and Durable Response To Anti-TNF Biologic Therapies in Crohn's Disease.
Barber GE; Yajnik V; Khalili H; Giallourakis C; Garber J; Xavier R; Ananthakrishnan AN
Am J Gastroenterol; 2016 Dec; 111(12):1816-1822. PubMed ID: 27596696
[TBL] [Abstract][Full Text] [Related]
40. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?
D'Haens GR; Panaccione R; Higgins PD; Vermeire S; Gassull M; Chowers Y; Hanauer SB; Herfarth H; Hommes DW; Kamm M; Löfberg R; Quary A; Sands B; Sood A; Watermeyer G; Lashner B; Lémann M; Plevy S; Reinisch W; Schreiber S; Siegel C; Targan S; Watanabe M; Feagan B; Sandborn WJ; Colombel JF; Travis S
Am J Gastroenterol; 2011 Feb; 106(2):199-212; quiz 213. PubMed ID: 21045814
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
